Loading...
Immunotherapies for Infectious Diseases Congress 2018

December 10 - 11 LYON - Matmut Stadium

News Twitter

Programme

schedule & speakers

Your company develops immunotherapies for infectious diseases and you want to present your scientific work at the I4ID 2018 congress? Check-out our sponsors & partners page to discover our sponsored presentation opportunities.

Day 1

Monday 10 December 2018

8h30

Registration & welcome coffee

9h00

Welcome address

9h15

Keynote Lecture

Prof. Stefan H. Kaufmann

Prof. Stefan H. Kaufmann
Director
Max Planck Institute for Infection Biology, Germany
Professor
Charité University Clinics, Germany
Tuberculosis control: the need for better diagnosis, therapy and prevention

10h00

Session I – Targeting the Immune system to fight Bacterial Infections

Caroline Demangel

Caroline Demangel
Head of Immunobiology of Infection Unit
Institut Pasteur and INSERM U1221, France
Protein translocation blockade: a novel mechanism of immune evasion by Mycobacterium ulcerans

10h30

Coffee break & Poster Session at Exhibition Hall | Partnering (B2B meetings)

11h00

Session I – Targeting the Immune system to fight Bacterial Infections

Willem Hanekom

Willem Hanekom
Deputy Director, TB (Vaccines)
Bill & Melinda Gates Foundation, USA

Wayne Dankner

Wayne Dankner
Chief Medical Officer
Atox Bio, Israel

12h00

Lunch break

13h00

Poster Session – Poster presentations at Exhibition Hall

14h00

Session II – Targeting the Immune System to fight Sepsis

Dr. Richard Hotchkiss

Dr. Richard Hotchkiss
Professor of Anesthesiology, Medicine, and Surgery
Washington University School of Medicine, USA
Physician
Surgical Intensive Care Unit at Barnes Jewish Hospital in St Louis, USA
Immunotherapy of Sepsis – a new approach to a lethal disease

Prof. Guillaume Monneret

Prof. Guillaume Monneret
Head of Clinical Cellular Immunology Laboratory
Lyon University Hospitals, France
Head of EA 7426 - research unit on Pathophysiology of injury-induced immunosuppression
Lyon University, France
Monitoring immune alterations: toward personalized immunotherapy in sepsis

Desiree Perlee

Desiree Perlee
PhD student
Center of Experimental & Molecular Medicine, University of Amsterdam, Netherlands
Stem cells as a possible treatment for sepsis

Dr. Fabienne Venet

Dr. Fabienne Venet
Associated Professor, Physician
Lyon University Hospitals
EA 7426 - research unit on Pathophysiology of injury-induced immunosuppression
Joint Research Unit bioMérieux-Hospices Civils de Lyon-Université Claude Bernard Lyon 1, France

16h00

Coffee break & Poster Session at Exhibition Hall | Partnering (B2B meetings)

16h30

Pitch Session – Innovation on HDT approaches to treat Infectious Diseases

Selection of the best 10 abstracts to give a 10min talk.

18h00

End of Day One

20h00

Cocktail Reception and Networking

Day 2

Tuesday 11 December 2018

8h00

Welcome coffee

8h30

Keynote Lecture

9h30

Session III – Targeting the Immune System to fight Viral Infections

Prof. Mala Maini

Prof. Mala Maini
Professor of Viral Immunology and Honorary Consultant
Division of Infection and Immunity at UCL, UK
Manipulating defective T cell immunity for HBV functional cure

10h30

Coffee break & Poster Session at Exhibition Hall | Partnering (B2B meetings)

11h00

Session III – Targeting the Immune System to fight Viral Infections

Dr. Carolina Boni

Dr. Carolina Boni
Researcher
University Hospital of Parma, Italy

David Durantel

David Durantel
Senior Researcher in Molecular Virology
INSERM, France

12h00

Lunch break

13h00

Poster Session – Poster presentations at Exhibition Hall

14h00

Session IV – Bringing into clinic Host-Directed Therapies: safety and efficiency

Pierre-François Laterre

Pierre-François Laterre
Head of the ICU
St. Luc University Hospital, UCL, Belgium

Michel Doubovetzky

Michel Doubovetzky
Head Non Clinical Safety Vaccines and Infectious Diseases
Sanofi, France

Mark Miller

Mark Miller
Executive Vice President, Chief Medical Officer
bioMérieux, France
Companion, supportive and facilitating diagnostics for immunotherapy: why are we failing compared to oncology?

15h30

Coffee Break & Poster Session at Exhibition Hall | Partnering (B2B meetings)

16h00

Session V – Developing Next-Generation of host-directed therapies

Eric Meldrum

Eric Meldrum
Chief Scientific Officer
Enyo Pharma, France

Nicolas Manel

Nicolas Manel
Team Leader
Institut Curie, France
Research Director
INSERM, France
Unraveling the innate immune sensors of viruses

Dr. Rafael Mañez

Dr. Rafael Mañez
Director of Critical Care Medicine
Bellvitge University Hospital, Spain
Head of the research group Innate Immunity and Pathology of the Critical Patient
Bellvitge Biomedical Research Institute (IDIBELL), Spain
Hospitalet de Llobregat Barcelona, Spain
Founder
RemAb Therapeutics, Spain
Removal of non-killing antibodies elicits protective immunity against infections

17h30

Announcement of the Best Pitch & Best Poster

17h45

Closing remarks

18h00

End of Congress